Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 307 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Treatment of Acute Myeloblastic Leukemia in Younger Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Treatment				Closed				65 and under				Other				AML99<=65 años NCT00390715


2.		PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				15 and over				Other				LAL-RI/96 NCT00494897

Last Modified: 12/1/1998


3.		Phase II/III Randomized Study of Monoclonal Antibody HuM195 As Maintenance Therapy in Elderly Patients with Acute Myeloid Leukemia in Complete Remission Following Chemotherapy (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				60 and over				Pharmaceutical / Industry				PDL-3-251 MSKCC-93131, NCI-V94-0469


4.		Phase II-III VCR/PRED/L-ASP Induction, CNS Therapy plus MTX vs 6-MP/MTX vs 6-MP/MTX/CTX vs 6-MP/MTX/CTX/ARA-C for Pediatric ALL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 18								SJCRH-ALL-TT-8


5.		Phase II/III Chemotherapy with DNM/ARA-C Induction and DNM/ARA-C/TG, DNM/AZC, and ARA-C/TG Maintenance for Acute Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 60								NCI-D81-018-590 DFCI-80035


6.		Phase II/III Consolidation Chemotherapy with VP-16/AMSA/AZC Following Induction with DNM/ARA-C/TG for Adult Primary or Secondary Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								NCI-D82-051-605

Last Modified: 8/10/2007


7.		Phase II/III Pilot Combination Chemotherapy and Radiotherapy for Previously Untreated Childhood ALL with Poor Prognosis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21				NCI				CCG-192P

Last Modified: 3/14/2007


8.		Phase II/III Randomized Comparison of Up-Front Alternating Chemotherapy vs Up-Front Intensive 6-MP/MTX for Poor Prognosis Childhood ALL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				1 to 20				NCI				POG-8698

Last Modified: 4/20/2006


9.		Phase II/III Pilot Study of Induction and Intensification Chemotherapy with VP-16, ARA-C, DNR, 5-AZ, and m-AMSA, Using "Modelled" Plasma Drug Concentrations of VP-16 and ARA-C, in Children with Acute Nonlymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21				NCI				SJCRH-AML-87 NCI-T86-0203D, T86-0203

Last Modified: 7/11/2007


10.		Phase II/III Randomized Study of MP/MTX vs DCF/MP/MTX in Patients with Relapsed T-ALL or T-NHL Who Achieve Second Remission Following Induction with PVDA (PRED/VCR/DNR/ASP)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				21 and under				NCI				POG-8862

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute